T-10 represents an innovative synthetic peptide designed as a dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) receptor and a second key metabolic receptor. This design incorporates advanced peptide engineering to achieve balanced activity at both receptor systems. The compound consists of a 39-amino acid linear peptide chain with structural similarities to hormones that activate these receptors, belonging to the secretin family of gut hormones. The peptide incorporates specific amino acid modifications designed to optimize binding affinity and activation of both target receptors.

The compound features a C20 fatty diacid modification that significantly enhances stability and extends half-life through albumin binding, similar to other long-acting peptide therapeutics. This modification allows for sustained biological activity and makes T-10 suitable for research protocols requiring prolonged receptor activation. The dual receptor activity profile provides unique opportunities for investigating the combined effects of signaling pathways from both receptors in metabolic regulation.

T-10 functions through simultaneous activation of both GIP and the second metabolic receptor, leading to complementary signaling cascades that influence glucose homeostasis, insulin secretion, and metabolic regulation. The compound’s dual mechanism involves activation of adenylyl cyclase at both receptor systems, resulting in increased cyclic adenosine monophosphate (cAMP) levels and downstream effects on pancreatic beta cells, adipose tissue, and other metabolically active tissues.